ARCHER
85 evidence topics · 31 sources
Objective
Registered objective: effect of intravitreal ANX007 on GA lesion growth rate
Location and study date
Registered study dates
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2021-02-26” |
| Primary completion (actual) | “2023-03-28” |
| Study completion (actual) | “2023-09-13” |
Study site countries
| Country | Example site location in the registry record |
|---|---|
| United States | “Boston, Massachusetts, United States” |
| Australia | “Adelaide, South Australia, Australia” |
| New Zealand | “Wellington, New Zealand” |
Share of participants enrolled in the United States
Study design
Registered design elements
| Design element | Registry record |
|---|---|
| Phase | “Phase 2” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |
Randomized, double-masked, sham-controlled design with stratification
Twelve-month treatment period followed by six months off treatment
Eligibility criteria
Key inclusion criteria
Key exclusion criteria
Enrollment of participants at high risk of progression
Treatment
Registered arms and interventions
| Arm | Quoted registry description |
|---|---|
| ANX007 Group 1, experimental | “ANX007 administered every month” |
| ANX007 Group 2, experimental | “ANX007 administered every other month” |
| Sham Group 3, sham comparator | “Sham injection administered every month” |
| Sham Group 4, sham comparator | “Sham injection administered every other month” |
| ANX007 formulation and route | “Form: solution for injection; Route of Administration: IVT” |
| Sham procedure | “Form and Route of Administration: pressure to mimic IVT injection” |
Dose, schedule, and randomized arms
Injection volume in phase 2
Dosing schedules planned at trial initiation
Study outcomes
Rationale for using rate of change in geographic atrophy lesion area by fundus autofluorescence as the primary endpoint
Primary endpoint definition: GA lesion area slope by FAF through Month 12
Sponsor rationale at trial start: natural history data and enrichment for fast progressors
Non-foveal lesions as a risk factor for faster lesion growth
Regulatory acceptance of GA expansion measured by FAF
“After extensive discussions, the FDA agreed that an acceptable clinical endpoint for GA could be the rate or extent of anatomic progression of GA in treatment and placebo groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fundus autofluorescence (FAF) imaging is the standard metric used by the FDA for assessing GA expansion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the relationship between function and altered autofluorescence at the GA border is still not clear.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor view after the readout: FAF measures the retinal pigment epithelium
Prespecified visual function endpoints
Best corrected visual acuity: ETDRS letter score
BCVA loss of 15 or more letters: definition and rationale
Low-luminance visual acuity and low-luminance deficit
Statistical analysis description
Number of participants (Planned and analyzed)
Participants enrolled
| Enrollment type | Participants |
|---|---|
| Actual | “270” |
Optical coherence tomography subpopulation
Description of analysis sets
Intent-to-treat and safety populations
Primary endpoint analysis population: non-subfoveal participants
Low-luminance event analyses: participants with a postbaseline measurement
Primary endpoint model: linear mixed effect model
Visual acuity analyses: chi-square test and MMRM in the ITT population
Optical coherence tomography analysis population
Results
Participant disposition
Registry participant flow through the overall study
| Milestone or reason | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Started | “89” | “92” | “89” |
| Received at least 1 dose of study drug | “89” | “92” | “89” |
| Completed | “73” | “77” | “76” |
| Not completed | “16” | “15” | “13” |
| Adverse event | “4” | “7” | “3” |
| Death | “0” | “0” | “1” |
| Lost to follow-up | “2” | “2” | “1” |
| Other than specified | “1” | “0” | “1” |
| Physician decision | “1” | “0” | “1” |
| Protocol violation | “1” | “1” | “0” |
| Withdrawal by subject | “7” | “5” | “6” |
Counts reported per participant
Treatment discontinuation by arm
| Measure | Sham pooled | ANX007 EM | ANX007 EOM |
|---|---|---|---|
| Discontinued treatment | “10 (11.2%)” | “13 (14.6%)” | “11 (12.0%)” |
Baseline characteristics
Registry baseline characteristics, ITT population
| Characteristic | ANX007 EM | ANX007 EOM | Sham | Total |
|---|---|---|---|---|
| Participants | “89” | “92” | “89” | “270” |
| Age, years, mean (SD) | “79.7(8.64)” | “80.5(8.53)” | “79.8(7.49)” | “80.0(8.22)” |
| Female, participants | “47” | “60” | “59” | “166” |
| Male, participants | “42” | “32” | “30” | “104” |
| Hispanic or Latino, participants | “1” | “2” | “3” | “6” |
| White, participants | “87” | “89” | “87” | “263” |
| Asian, participants | “1” | “2” | “2” | “5” |
| Study eye GA lesion size, mm², mean (SD) | “7.2789(3.96342)” | “7.5284(4.09946)” | “7.2802(3.98783)” | “7.3643(4.00505)” |
| BCVA, ETDRS letters, mean (SD) | “58.8(17.19)” | “57.9(15.30)” | “58.5(16.23)” | “58.4(16.19)” |
| LLVA, ETDRS letters, mean (SD) | “35.3(16.41)” | “29.6(15.72)” | “34.2(18.05)” | “33.0(16.86)” |
| LLVA and LLVD, participants analyzed | “87 participants” | “91 participants” | “85 participants” | “263 participants” |
| LLVD, ETDRS letters, mean (SD) | “23.5(16.08)” | “28.3(18.39)” | “25.0(15.70)” | “25.7(16.86)” |
Lesion location, lesion size category, fellow-eye CNV, and multifocality
| Characteristic | Sham pooled (N=89) | Vonaprument EM (N=89) | Vonaprument EOM (N=92) |
|---|---|---|---|
| Foveal lesion | “49.4%” | “57.3%” | “53.3%” |
| GA lesion < 7.5 mm² | “61.8%” | “58.4%” | “57.6%” |
| Fellow eye CNV | “22.5%” | “24.7%” | “17.4%” |
| Multifocality, n (%) | “65 (73.0%)” | “61 (68.5%)” | “67 (72.8%)” |
Company summary of baseline characteristics
Efficacy results
Primary endpoint: rate of change in geographic atrophy lesion area through month 12, registry results
| Measure | ANX007 EM | ANX007 EOM | ANX007 Pooled | Sham |
|---|---|---|---|---|
| Participants analyzed | “38” | “43” | “81” | “45” |
| Rate of change (slope), mean (SE), mm²/year | “1.9902(0.36343)” | “2.1575(0.34824)” | “2.0837(0.30177)” | “1.9019(0.34239)” |
| Change from baseline to month 12, least squares mean (SE), mm² | “2.3547(0.26452)” | “2.5782(0.24317)” | “2.4835(0.18003)” | “2.3170(0.23142)” |
Primary endpoint: company-reported reduction in lesion growth
Lesion growth by study period: additional analysis
Confirmed BCVA ≥15-letter loss: registry event counts, secondary outcome
Confirmed BCVA ≥15-letter loss: topline company counts and event definition
| Measure | Sham (n=89) | EM (n=89) | EOM (n=92) | ANX007 pooled (n=181) |
|---|---|---|---|---|
| Participants with ≥15-letter loss through month 12 | “21.3% (19/89)” | “5.6% (5/89)” | “10.9% (10/92)” | “8.3% (15/181)” |
| p-value vs sham | “--” | “0.0021” | “0.055” | “0.0024” |
Confirmed BCVA ≥15-letter loss: final data under two event definitions
| Event definition and measure | Sham | Vonaprument EM | Vonaprument EOM |
|---|---|---|---|
| Through month 12 or last visit: participants with loss | “19/89” | “5/89” | “9/92” |
| Through month 12 or last visit: percentage | “21.3%” | “5.6%” | “9.8%” |
| Through month 12 or last visit: nominal p-value vs pooled sham | “---” | “0.0021” | “0.032” |
| Month 12 event confirmed at month 15: participants with loss | “15/89” | “4/89” | “8/92” |
| Month 12 event confirmed at month 15: percentage | “16.9%” | “4.5%” | “8.7%” |
| Month 12 event confirmed at month 15: nominal p-value vs pooled sham | “---” | “0.0076” | “0.0994” |
Confirmed BCVA ≥15-letter loss: analysis type and nominal significance
Time to confirmed BCVA ≥15-letter loss: Kaplan-Meier hazard ratios
“73% Risk Reduction Vonaprument EM” (opens the source at this quote in a new tab)
“HR (CI) = 0.272 (0.090 to 0.819); Nominal p = 0.0119” (opens the source at this quote in a new tab)
“50% Risk Reduction Vonaprument EOM” (opens the source at this quote in a new tab)
“HR (CI) = 0.504 (0.214 to 1.189); Nominal p = 0.1098” (opens the source at this quote in a new tab)
Time to confirmed BCVA ≥15-letter loss: hazard ratios as presented in 2024
“53% Risk Reduction ANX007 EOM” (opens the source at this quote in a new tab)
“HR (CI) = 0.504 (0.214 to 1.190); p = 0.0788” (opens the source at this quote in a new tab)
“73% Risk Reduction ANX007 EM” (opens the source at this quote in a new tab)
“HR (CI) = 0.272 (0.090 to 0.819); p = 0.0098” (opens the source at this quote in a new tab)
Confirmed BCVA ≥10-letter and ≥20-letter loss: sensitivity analysis
| Threshold and measure | Sham | EM | EOM |
|---|---|---|---|
| ≥10-letter loss: participants with loss | “23/89” | “14/89” | “19/92” |
| ≥10-letter loss: percentage | “25.8%” | “15.7%” | “20.7%” |
| ≥10-letter loss: nominal p-value vs sham | “---” | “0.096” | “0.408” |
| ≥20-letter loss: participants with loss | “15/89” | “4/89” | “6/92” |
| ≥20-letter loss: percentage | “16.9%” | “4.5%” | “6.5%” |
| ≥20-letter loss: nominal p-value vs sham | “---” | “0.008” | “0.030” |
Additional analyses of BCVA loss presented in 2023
BCVA ≥15-letter loss after treatment ended: off-treatment period
Mean change in BCVA from baseline to month 12
| Measure | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Participants analyzed | “89” | “92” | “89” |
| Mean (SE) change, letters | “-1.7(1.33)” | “-2.6(1.29)” | “-4.1(1.31)” |
Low-luminance visual acuity: registry results
| Measure | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Change from baseline to month 12, least squares mean (SE), letters | “-1.4(1.29)” | “-2.8(1.25)” | “-4.8(1.31)” |
| Participants analyzed for ≥15-letter loss | “79” | “85” | “79” |
| Number of events with ≥15-letter LLVA loss | “6” | “8” | “16” |
Low-luminance visual acuity ≥15-letter loss: topline company counts
| Measure | Sham (n=79) | EM (n=79) | EOM (n=85) | ANX007 pooled (n=164) |
|---|---|---|---|---|
| Participants with ≥15-letter LLVA loss through month 12 | “20.3% (16/79)” | “10.1% (8/79)” | “11.8% (10/85)” | “11.0% (18/164)” |
| p-value vs sham | “--” | “0.076” | “0.14” | “0.051” |
Low-luminance visual acuity and deficit: final data
| Measure | Sham | EM | EOM |
|---|---|---|---|
| LLVA ≥15-letter loss: participants with loss | “16/79” | “6/79” | “8/85” |
| LLVA ≥15-letter loss: percentage | “20.3%” | “7.6%” | “9.4%” |
| LLVA ≥15-letter loss: nominal p-value vs sham | “--” | “0.0216” | “0.0497” |
| LLVD ≥15-letter worsening: participants with worsening | “13/79” | “4/79” | “8/85” |
| LLVD ≥15-letter worsening: percentage | “16.5%” | “5.1%” | “9.4%” |
| LLVD ≥15-letter worsening: nominal p-value vs sham | “--” | “0.0209” | “0.1774” |
| Mean change in LLVA at month 12 | “-4.8” | “-1.4” | “-2.8” |
| Mean change in LLVA at month 12: nominal p-value vs sham | “---” | “0.0592” | “0.2664” |
Low-luminance visual acuity ≥15-letter loss: event definition as presented in 2024
Low-luminance visual deficit: registry results
| Measure | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Change from baseline to month 12, least squares mean (SE), letters | “-0.4(1.55)” | “1.3(1.50)” | “0.6(1.57)” |
| Participants analyzed for ≥15-letter worsening | “79” | “85” | “79” |
| Number of events with ≥15-letter LLVD worsening | “4” | “8” | “13” |
Ellipsoid zone loss: photoreceptor preservation across the macula and in central subdomains
| Region | Sham participants | Vonaprument pooled participants | Reduction vs sham | Nominal p-value |
|---|---|---|---|---|
| Pan-macula, total EZ loss | “Sham (n = 67)” | “Vonaprument pooled (n = 107)” | “27% decrease” | “0.0457” |
| Central 2.0 mm, total EZ loss | “Sham (n = 25)” | “Vonaprument pooled (n = 36)” | “48% decrease” | “0.0218” |
| Central 1.5 mm, total EZ loss | “Sham (n = 22)” | “Vonaprument pooled (n = 24)” | “59% decrease” | “0.0319” |
Ellipsoid zone and central retinal pigment epithelium loss: results as reported in 2024
Subgroup analysis: BCVA ≥15-letter loss by lesion location
| Lesion location | Sham | EM | EOM | ANX007 pooled |
|---|---|---|---|---|
| Foveal | “25.0% (11/44)” | “5.9% (3/51)” | “18.4% (9/49)” | “12.0% (12/100)” |
| Non-foveal | “17.8% (8/45)” | “5.3% (2/38)” | “2.3% (1/43)” | “3.7% (3/81)” |
| p-value vs sham | “--” | “0.0019” | “0.0439” | “0.0015” |
Subgroup analysis: BCVA ≥15-letter loss by baseline low-luminance visual deficit
| Baseline LLVD | Sham | EM | EOM | ANX007 pooled |
|---|---|---|---|---|
| LLVD <30 (healthier) | “16.9% (10/59)” | “0.0% (0/56)” | “6.3% (3/48)” | “2.9% (3/104)” |
| LLVD ≥30 (less healthy) | “30.8% (8/26)” | “16.1% (5/31)” | “16.3% (7/43)” | “16.2% (12/74)” |
| p-value vs sham | “--” | “0.0016” | “0.029” | “0.0009” |
Subgroup analysis: low-luminance visual deficit worsening by baseline BCVA
| Baseline BCVA score | Sham | EM | EOM | ANX007 pooled |
|---|---|---|---|---|
| ≥55 (better vision) | “25.5% (13/51)” | “9.4% (5/53)” | “16.4% (9/55)” | “13.0% (14/108)” |
| <55 (impaired vision) | “17.9% (5/28)” | “7.7% (2/26)” | “3.3% (1/30)” | “5.4% (3/56)” |
| p-value vs sham | “--” | “0.0161” | “0.0597” | “0.0091” |
Post hoc analysis: participants with subfoveal lesions at baseline
| Measure, subfoveal population | Sham | Vonaprument EM | Vonaprument EOM |
|---|---|---|---|
| Confirmed BCVA ≥15-letter loss: participants with loss | “10/44” | “3/51” | “7/49” |
| Confirmed BCVA ≥15-letter loss: percentage | “22.7%” | “5.9%” | “14.3%” |
| Confirmed BCVA ≥15-letter loss: nominal p-value vs sham | “---” | “.0172” | “.2930” |
| LLVA ≥15-letter loss: participants with loss | “7/41” | “2/50” | “1/48” |
| LLVA ≥15-letter loss: percentage | “17.1%” | “4.0%” | “2.1%” |
| LLVA ≥15-letter loss: nominal p-value vs sham | “---” | “.0137” | “.0377” |
“76% Risk Reduction Vonaprument EM” (opens the source at this quote in a new tab)
“HR (CI) = 0.242 (0.067 to 0.881); Nominal p = .0204” (opens the source at this quote in a new tab)
“41% Risk Reduction Vonaprument EOM” (opens the source at this quote in a new tab)
“HR (CI) = 0.504 (0.225 to 1.555); Nominal p = .2784” (opens the source at this quote in a new tab)
Baseline characteristics associated with BCVA ≥15-letter loss
Number needed to treat
“Number Needed to Treat = 1 / (21.3 – 5.6) * 100= 6.4” (opens the source at this quote in a new tab)
“Number Needed to Treat EM To Avoid ≥10 LL = 10” (opens the source at this quote in a new tab)
“Number Needed to Treat EM To Avoid ≥15 LL = 7” (opens the source at this quote in a new tab)
“Number Needed to Treat EM To Avoid ≥20 LL = 8” (opens the source at this quote in a new tab)
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events through month 12, registry results
Deaths, serious adverse events, and other adverse events, registry results
| Measure | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| All-cause mortality | “2/89 (2.25%)” | “3/92 (3.26%)” | “2/89 (2.25%)” |
| Participants with serious adverse events | “21/89 (23.60%)” | “16/92 (17.39%)” | “16/89 (17.98%)” |
| Participants with other (non-serious) adverse events | “21/89 (23.60%)” | “20/92 (21.74%)” | “23/89 (25.84%)” |
Ocular serious adverse events, registry results
| Serious adverse event | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Endophthalmitis | “1/89 (1.12%)” | “2/92 (2.17%)” | “0/89 (0.00%)” |
| Retinal artery occlusion | “0/89 (0.00%)” | “1/92 (1.09%)” | “0/89 (0.00%)” |
| Neovascular age-related macular degeneration | “1/89 (1.12%)” | “0/92 (0.00%)” | “0/89 (0.00%)” |
| Dry age-related macular degeneration | “1/89 (1.12%)” | “0/92 (0.00%)” | “0/89 (0.00%)” |
| Iritis | “1/89 (1.12%)” | “0/92 (0.00%)” | “0/89 (0.00%)” |
| Vitritis | “0/89 (0.00%)” | “1/92 (1.09%)” | “0/89 (0.00%)” |
| Vitreous floaters | “1/89 (1.12%)” | “0/92 (0.00%)” | “0/89 (0.00%)” |
| Visual acuity reduced | “0/89 (0.00%)” | “0/92 (0.00%)” | “1/89 (1.12%)” |
Non-ocular serious adverse events in two or more participants in any group, registry results
| Serious adverse event | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Atrial fibrillation | “2/89 (2.25%)” | “4/92 (4.35%)” | “0/89 (0.00%)” |
| Acute myocardial infarction | “2/89 (2.25%)” | “1/92 (1.09%)” | “0/89 (0.00%)” |
| Angina pectoris | “0/89 (0.00%)” | “2/92 (2.17%)” | “0/89 (0.00%)” |
| Pneumonia | “3/89 (3.37%)” | “2/92 (2.17%)” | “0/89 (0.00%)” |
| Urinary tract infection | “1/89 (1.12%)” | “1/92 (1.09%)” | “2/89 (2.25%)” |
| Cerebrovascular accident | “2/89 (2.25%)” | “0/92 (0.00%)” | “2/89 (2.25%)” |
Non-serious adverse events at a frequency of 5% or more, registry results
| Adverse event | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| COVID-19 | “12/89 (13.48%)” | “10/92 (10.87%)” | “10/89 (11.24%)” |
| Urinary tract infection | “6/89 (6.74%)” | “7/92 (7.61%)” | “12/89 (13.48%)” |
| Conjunctival haemorrhage | “7/89 (7.87%)” | “6/92 (6.52%)” | “3/89 (3.37%)” |
Adverse events of special interest: choroidal neovascularization, endophthalmitis, vascular occlusion, vasculitis, intraocular inflammation, and ischemic optic neuropathy
| Adverse event, n (%) | Sham (N=89) | Vonaprument EM (N=89) | Vonaprument EOM (N=92) |
|---|---|---|---|
| Choroidal neovascularization | “3 (3.4%)” | “4 (4.5%)” | “4 (4.3%)” |
| Endophthalmitis | “0” | “1 (1.1%)” | “2 (2.2%)” |
| Retinal vascular occlusion | “0” | “0” | “1^ (1.1%)” |
| Retinal vasculitis | “0” | “0” | “0” |
| Intraocular inflammation | “0” | “2 (2.2%)” | “1 (1.1%)” |
| Ischemic optic neuropathy | “0” | “0” | “0” |
“Iritis – 1” (opens the source at this quote in a new tab)
“Resolved with topical steroids in 2 days” (opens the source at this quote in a new tab)
“Vitritis – 1” (opens the source at this quote in a new tab)
“Resolved with topical steroids in 9 days” (opens the source at this quote in a new tab)
“Vitreous Debris – 1” (opens the source at this quote in a new tab)
“Not AESI, included because of current interest” (opens the source at this quote in a new tab)
Endophthalmitis, intraocular inflammation, and retinal artery occlusion: topline description
Choroidal neovascularization and retinal vasculitis
Study limitations
Summary: missed primary endpoint, reliance on secondary and post hoc analyses, and unpublished results
- Primary endpoint: ARCHER did not meet its primary endpoint, the rate of change (slope) in geographic atrophy lesion area by fundus autofluorescence from baseline to month 12. In the registry analysis, which included non-subfoveal participants only, the slope was 2.0837 mm²/year in 81 participants receiving pooled vonaprument and 1.9019 mm²/year in 45 participants receiving sham. Annexon reported reductions in lesion growth of 6.2% with monthly dosing (p=0.526), 1.3% with every-other-month dosing (p=0.896), and 3.7% for the pooled groups (p=0.673).
- Efficacy claims rest on secondary, exploratory, and post hoc analyses: BCVA ≥15-letter loss is a secondary outcome on the registry record and is labeled “A Prespecified Secondary Analysis” in a 2025 presentation. The Form 10-K describes the monthly-arm result as “nominally statistically significant”, and the company presentations of 2024 to 2026 label their p-values as nominal. The analyses of eyes with subfoveal lesions are labeled post hoc, and the company describes the analyses of less advanced disease, BCVA ≥10-letter and ≥20-letter loss, fellow eyes, and the off-treatment period as additional or sensitivity analyses. Mean change in BCVA at month 12 was -1.7 letters with monthly dosing, -2.6 with every-other-month dosing, and -4.1 with sham, with nominal p-values of 0.1904 and 0.3977.
- Discrepant event counts: the registry reports 4, 8, and 15 events of confirmed BCVA ≥15-letter loss (monthly, every other month, sham), defined as loss at 2 consecutive visits. The topline release reported 5 of 89 (5.6%), 10 of 92 (10.9%), and 19 of 89 (21.3%) participants, counting loss on two consecutive visits or a loss at the end of the 12-month treatment period. The 2026 presentation reports 5 of 89, 9 of 92, and 19 of 89 under “two consecutive visits through month 12 or at last study visit” (nominal p=0.0021 and 0.032), and 4 of 89, 8 of 92, and 15 of 89 when the month 12 event is confirmed at month 15 (nominal p=0.0076 and 0.0994). Under the definition that reproduces the registry counts, the every-other-month result is not nominally significant.
- Changing analyses between presentations: the topline release reported LLVA ≥15-letter loss in 8 of 79 participants (10.1%) with monthly dosing and 16 of 79 (20.3%) with sham (p=0.076), described as a “non-significant trend”. Later presentations report 6 of 79 (7.6%) with p=0.022 or 0.0216; the 2024 presentation attributes these counts to a “single LLVA ≥15-letter loss event”, and the 2026 presentation attributes the same counts to “two consecutive or last visit 15-letter loss events”. The nominal p-value for the monthly hazard ratio of 0.272 is 0.0098 in the 2024 presentation and 0.0119 in the 2026 presentation, and for the every-other-month hazard ratio of 0.504 it is 0.0788 and 0.1098. The ellipsoid zone result across the full retinal field was 29% (p=0.017) in the 2024 release and a 27% decrease (p=0.0457) in 107 vonaprument and 67 sham participants in the 2026 presentation; the central 1.5 mm and 2.0 mm subdomain analyses include 46 and 61 participants.
- No peer-reviewed publication: no journal article reporting ARCHER results was identified. The registry record states a restrictive agreement under which investigator-initiated publications wait until all protocol-defined results are published in a manuscript. The available results come from the registry, press releases, the Form 10-K, investor presentations, and congress presentations that state Annexon sponsorship, with authors who are employees and equity owners of Annexon Biosciences.
- Applicability: the treatment period was 12 months, followed by 6 months off treatment, during which the rate of BCVA ≥15-letter loss in the treated groups increased to parallel sham. Ninety-six percent of participants were enrolled in the United States. ARCHER II did not enroll individuals with baseline BCVA <45 letters, because ARCHER showed a very low incidence of BCVA 15-letter loss in that group, so the phase 3 population differs from the phase 2 population. The phase 3 trial tests monthly dosing only.